Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD

Inclusion Criteria:

• Age ≥ 50 years

• A diagnosis of choroid neovascularization (CNV) secondary to AMD with CNV comprisingat least 50% of the total lesion area on fluorescein angiography (FA)

• Central subfield thickness (spectral domain (SD)-OCT central 1 mm) of ≥ 300 μm

• Best-corrected visual acuity (BCVA) 20/40 to 20/320 (73- to 24-letter score on theEarly Treatment of Diabetic Retinopathy Study [ETDRS] chart)

Exclusion Criteria:

• Neovascularization secondary to any other condition than AMD in the study eye; Bloodoccupying greater than 50% of the AMD lesion, or blood > 1.0 sq. mm underlying thefovea

• Pigment epithelial detachment (PED) without associated subretinal fluid and/or cysticretinal changes

• Clinical evidence of diabetic retinopathy or diabetic macular edema in the study eye

• Confounding ocular conditions in the study eye which will affect interpretation ofOCT, VA or assessment of macular appearance (e.g., cataract, epiretinal membrane,retinal vascular occlusive disease)

• Fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the studyeye or any condition preventing VA improvement

• Uncontrolled glaucoma in the study eye, or currently receiving topical glaucomamedication in the study eye